Summary
March 2008, Vol. 7, No. 2, Pages 147-158 , DOI 10.1517/14740338.7.2.147

Drug-induced crystal nephropathy: an update

Sri G Yarlagadda1 MD & Mark A Perazella2 MD FACP
1Yale University School of Medicine, Section of Nephrology/Department of Medicine, LMP 2071, 333 Cedar Street, New Haven, CT 06520-8029, USA
2Associate Professor of Medicine Yale University School of Medicine, Section of Nephrology/Department of Medicine, LMP 2071, 333 Cedar Street, New Haven, CT 06520-8029, USA +1 203 785 4184; +1 203 785 7068;
Author for correspondence



Background: Several medications that are insoluble in human urine are known to precipitate within the renal tubules. Intratubular precipitation of either exogenously administered medications or endogenous crystals (induced by certain drugs) can promote chronic and acute kidney injury, termed crystal nephropathy. Clinical settings that enhance the risk of drug or endogenous crystal precipitation within the kidney tubules include true or effective intravascular volume depletion, underlying kidney disease, and certain metabolic disturbances that promote changes in urinary pH favoring crystal precipitation. Objective: Identify and review previously described and recently recognized medications that cause crystal nephropathy. Method: A literature review was performed, using PubMed, Ovid, and Google Scholar, focusing on drugs (sulfadiazine, acyclovir, indinavir, triamterene, methotrexate (MTX), orlistat, oral sodium phosphate preparation, ciprofloxacin) that cause crystal nephropathy. Results/conclusion: Sulfadiazine, acylcovir, indinavir, triamterene, and MTX are known to cause crystal nephropathy. Recently, several medications, including orlistat, ciprofloxacin, and oral sodium phosphate solution, along with underlying risk factors have been described as causing crystal nephropathy.

Full Text | PDF (1317 KB) | PDF Plus (1466 KB)

Forward Links to Citing Articles

B. A. Vervaet, A. Verhulst, P. C. D'Haese, M. E. De Broe. (2009) Nephrocalcinosis: new insights into mechanisms and consequences. Nephrology Dialysis Transplantation 24:7, 2030-2035
Online publication date: 1-Aug-2009.
CrossRef
Kjeld Schmiegelow. (2009) Advances in individual prediction of methotrexate toxicity: a review. British Journal of Haematology
Online publication date: 1-Jul-2009.
CrossRef
Christoph Boesecke, David A Cooper. (2008) Toxicity of HIV protease inhibitors: clinical considerations. Current Opinion in HIV and AIDS 3:6, 653-659
Online publication date: 1-Dec-2008.
CrossRef

Users who read this article also read:

The epidemiology of drug-induced disorders: the kidney
Stephanie S Taber, Deborah A Pasko
Expert Opinion on Drug Safety, Nov 2008, Vol. 7, No. 6, Pages 679-690.
Summary | Full Text | PDF (249 KB) | PDF Plus (265 KB) | Add to Favorites | Related 
 

Prev. Article | Next Article
View/Print PDF (1317 KB)
View PDF Plus (1466 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Sri G Yarlagadda
Mark A Perazella
Keywords:
acute kidney injury
crystal nephropathy
crystalluria
intratubular obstruction
medications